Why Cell and Gene Therapies Cost So Much – And What Can Be Done
Is Business Broken?
Navigating the Approval Maze for Innovative Therapies
This chapter delves into the challenges insurers face in approving and reimbursing high-cost cell and gene therapies, underscoring the need for clearer policies to support patient access. It also explores emerging financial solutions, including risk-sharing agreements between biotech companies and insurers to facilitate coverage decisions.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
